Coronavirus disease 2019 (COVID-19) is highly infectious. It has been highlighted that if not expertly and individually managed with consideration of the vasocentric features, a COVID-19 patient with an acute respiratory distress syndrome (CARDS) may eventually develop multiorgan failure. Unfortunately, there is still no definite drug for CARDS that is capable of reducing either short-term or long-term mortality and no specific treatments for COVID-19 exist right now. In this narrative review, based on a selective literature search in EMBASE, MEDLINE, Scopus, The Cochrane Library, Web of Science, and Google Scholar and ClinicalTrials.gov, we have examined the emerging evidence on the possible treatment of CARDS. Although numerous pharmacologic therapies to improve clinical outcomes in CARDS have been studied also in clinical trials, none have shown efficacy and there is great uncertainty about their effectiveness. There is still no recommendation for the therapeutic use of any specific agent to treat CARDS because no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale trials. However, there exist a number of drugs that may be useful at least in some patients. The real challenge now is to link the right patient to the right treatment.

2019 年冠状病毒病 (COVID-19) 具有高度传染性。有人强调，如果不考虑血管中心特征进行专业和个体化管理，患有急性呼吸窘迫综合征 (CARDS) 的 COVID-19 患者最终可能会出现多器官衰竭。不幸的是，目前还没有能够降低短期或长期死亡率的 CARDS 明确药物，目前也没有针对 COVID-19 的特定治疗方法。在这篇叙述性综述中，基于对 EMBASE、MEDLINE、Scopus、The Cochrane Library、Web of Science 以及 Google Scholar 和 ClinicalTrials.gov 的选择性文献检索，我们检查了有关 CARDS 可能治疗的新证据。尽管在临床试验中也研究了许多改善 CARDS 临床结果的药物疗法，没有一个显示出功效，而且它们的有效性存在很大的不确定性。仍然没有推荐使用任何特定药物来治疗 CARDS，因为在大规模试验中没有药物被证实在 COVID-19 患者的临床治疗中具有显着疗效。然而，有许多药物可能至少对某些患者有用。现在真正的挑战是将正确的患者与正确的治疗联系起来。